ENIn kidney cancer, immunotherapy became the backbone of drug treatment for advanced disease, yet there it is almost never used alone. It is usually a pair: one drug releases the brake on immune cells, the other cuts off the tumour’s blood supply, and the point is they work differently.
This page covers kidney cancer immunotherapy in Germany: the combinations used, treatment after kidney removal versus for metastases, what a risk group is and why the regimen depends on it, managing side effects of two drugs at once, and how a course works for a patient from abroad. The method in general: cancer immunotherapy in Germany.
Why kidney cancer is treated with a pair of drugs
A pair is used because renal cell cancer offers two points of attack, immune and vascular. It has a rich blood supply, making the body build new vessels for it: the vascular drug, a tyrosine kinase inhibitor, blocks those growth signals, while the immune drug releases the brake proteins PD-1 and CTLA-4 on T lymphocytes (immune cells).
Two kinds of pair are used: a PD-1 blocker with a drug against the tumour’s vessels, or two immune drugs, a PD-1 and a CTLA-4 blocker. Pairs differ in strength and side effects; choosing is a conversation with a doctor, not an online comparison of drug names.
Two immune drugs cause side effects more often and more severely than one. With an immune plus a vascular drug the picture is mixed: some complaints come from one, some from the other, and the doctor must work out which to pause. More on vessel drugs: targeted therapy in Germany.
After surgery and in metastatic disease: two different tasks
The tasks differ: preventing a return after surgery, holding back metastases. If the kidney or part of it was removed, no disease is visible but the risk of return is high, time-limited immunotherapy is discussed: so-called adjuvant, or post-operative, treatment. The pathology report decides, not a wish: stage, grade, surgical margins and whether metastases were removed.
In advanced disease treatment starts with drugs; removing the kidney itself is decided separately and not always first. Local methods, surgery or radiotherapy for a single metastasis, are discussed when lesions are few.
A risk group estimates prognosis from simple parameters: time from diagnosis to starting drugs, blood values and general condition. These place the patient in a favourable, intermediate or poor prognosis group, and the pair offered depends directly on it: nivolumab with ipilimumab is approved only for intermediate or poor prognosis. Knowing your group makes the regimen discussion easier to follow. More on stages: kidney cancer treatment in Germany.
What is established before treatment starts
First comes the subtype, which the pathology report must name: clear cell and non-clear cell variants of renal cell cancer behave differently, and their regimens are discussed separately. The material comes from the existing tissue block after surgery or biopsy; see tumour immunohistochemistry in Germany.
The work-up: imaging of abdomen and chest, plus bone and brain where lesions are suspected; function of the remaining kidney, on which doses and monitoring depend; liver and thyroid values and blood pressure, since vessel drugs raise it, which must be managed in advance, not after the fact.
The patient is asked about autoimmune disease, organ transplants and continuous steroids or immunosuppressants; each changes the decision. The case goes to a tumour board and the patient receives a written plan. Kidney follow-up after surgery: urology in Germany.
Side effects and monitoring
The two parts cause different side effects. The immune part can inflame healthy organs: skin, bowel, thyroid and other endocrine glands, liver, less often lungs, kidneys and heart. Fatigue is common.
The vascular part brings raised blood pressure, skin changes on palms and soles, an inflamed mouth lining, diarrhoea, thyroid changes and protein in the urine: unpleasant, but predictable and largely managed with the dose and supportive measures.
Monitoring means tests and an examination before each infusion, home blood pressure readings written down, kidney and thyroid checks, and repeat imaging at set intervals. The patient holds the on-call number and a list of signs that mean calling at once. Further reading in German: the German Cancer Research Centre’s cancer information service.
The course, the trip and the cost
The immune drug is given intravenously in a day unit every few weeks; the vessel drug is a tablet or capsule taken daily at home. Hence the realistic pattern for a traveller: starting treatment, dose finding and instruction in Germany, continuing at home under one’s own doctor on the German plan, returning for monitoring. This depends on the drugs being available in the patient’s country.
The estimate depends on the drugs and number of infusions, the day unit, tests before the start and at monitoring, and the tumour board; pathology and molecular work count separately if repeated in Germany. See cost of immunotherapy in Germany.
Frequently asked questions
Can kidney cancer be treated with immunotherapy alone?
In metastatic disease, almost never: for first treatment the German guideline recommends pairs, an immune drug with a vessel drug or two immune drugs. A single immune drug is used after kidney removal when the risk of return is high, for a limited period.
How long does immunotherapy for kidney cancer last?
It depends on the task. After surgery the course lasts up to one year unless the cancer returns or side effects force a stop. With metastases treatment is usually long-term, continuing while the disease does not progress and the drugs are tolerated.
Does immunotherapy help in metastatic kidney cancer?
It can relieve symptoms, improve quality of life and prolong life, but no one can predict how a given tumour will respond. With metastases the aim is almost always control, not cure. If imaging shows a regimen failing, or it is poorly tolerated, the tumour board proposes another.
How AlenMed arranges kidney cancer immunotherapy in Germany
We collect the pathology report stating the subtype, imaging, blood results and post-surgery discharge letters, pass them to oncologists and uro-oncologists at partner hospitals that treat renal cell cancer regularly, and learn which regimen they find appropriate here and what they advise against, before any figure is named. Then: a written plan, an estimate, a visa invitation, an interpreter at appointments, accommodation between infusions.
The patient should plan how many days the first trip takes, who answers a question about blood pressure or a rash a month after returning, and how tolerability data reach the German doctor.
This material is for reference only and is not an offer; the indication and regimen are decided by a doctor in person.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
